Please assess the completion status of the following clinical trial:

Trial Title: Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Signed informed consent~* Female and male patients ≥ 18 years of age~* Histologically confirmed metastatic melanoma (stage IV, per AJCC staging), carrying BRAF V600-mutation~* Performed SRS 14 ±7 days before baseline using a harmonized protocol in patients with at least one measurable intracranial target lesion for which the following criteria are met:~  * Previously untreated (Lesions in previously irradiated area should not be selected)~ * Largest diameter of ≥ 0.5 but ≤ 4 cm as determined by contrast-enhanced MRI and~ * ≤ 10 brain metastases~* ECOG performance status 0 - 2~* Life expectancy ≥ 12 weeks~* Adequate bone marrow function as indicated by the following:~  * ANC ≥ 1500/µL,~ * Platelets ≥ 100,000/µL and~ * Hemoglobin ≥ 9 g/dL~* Adequate renal function, as indicated by creatinine ≤ 1.5 x ULN~* Adequate liver function, as indicated by bilirubin \< 1.5 x ULN and AST and ALT \< 3 x ULN (documented liver metastases: AST and ALT \< 5 x ULN)~* Adequate coagulation within 28 days prior to baseline visit~  * Patients without therapeutic anticoagulation: INR or aPTT ≤ 1.5 x ULN~ * Patients receiving therapeutic anticoagulation: stable anticoagulation regimen and stable INR~* Able to swallow pills~Exclusion criteria~* Symptomatic brain metastases requiring immediate local interventions such as neurosurgery or radiosurgery~* Leptomeningeal disease (also synchronous with brain metastases)~* Prior therapy with BRAF or MEK inhibitors within 12 weeks prior to baseline visit (prior therapies for metastatic melanoma including chemo-, cytokine-, immuno-, biological and vaccine-therapy will be al-lowed) A period of at least 6 weeks must be observed between the last dose of ipilimumab and the first administration of the study treatments. Prior treatment with anti-programmed cell death (PD)-1 or anti-PD ligand 1 (PD-L1) is allowed.~* Prior whole brain irradiation (Patients with prior local therapy of brain metas-tases are eligible)~* Patients receiving therapeutic steroids are not stable on corticoster-oids 2 weeks before SRS~* Active and uncontrolled infection~* Known HIV infection or active HBV or HCV infection~  * Active HBV infection (chronic and acute), defined as having a posi-tive hepatitis B surface antigen (HBsAg) test at screening (past or resolved HBV infection, defined as negative HBsAg test and a posi-tive total hepatitis B core antibody test at screening, are eligible)~ * Active HCV infection, defined as positive HCV antibody test and positive HCV RNA test at screening~* Intracranial radiation therapy within 14 days prior to SRS~* Extracranial radiation therapy within the last 14 days prior to baseline visit~* Treatment with strong CYP3A4/5 inhibitors (e.g. ketoconazole) and inducers (e.g. phenytoin, carbamazepine). (anticonvulsant levetiracetam is allowed; patient should be stable on levetiracetam for 2 weeks)~* Unresolved toxicity of National Cancer Institute Common Terminology Crite-ria for Adverse Events, version 4.0 (NCI v4.0) \[NCI, 2009\] Grade 2 or higher from previous anti-cancer therapy, except alopecia.~* Conditions that will interfere significantly with the absorption of drugs (e.g. Colitis ulcerosa)~* Inability to undergo MRI secondary to:~  * Metal,~ * Claustrophobia, or~ * Gadolinium contrast allergy~* Previous malignancies active within the last 3 years, with the exception of locally curable cancers that have been treated to complete remis-sion or untreated stage I chronic lymphoid leukemia.~* Unwillingness or inability to comply with study and follow-up procedures~* Known hypersensitivity to any of the excipients of cobimetinib and vemuraf-enib~* The following foods/supplements are prohibited at least 7 days prior to initia-tion of and during study treatment:~  * St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)~ * Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)~* Patient is included in another interventional trial~* Use of any investigational or non-registered product within 4 weeks prior to baseline visit~* Woman of childbearing age with the exception they meet at least one of the following criteria:~  * Post-menopausal,~ * Sterilization,~ * Consistently \& correct application of contraceptives (Pearl Index \< 1%),~ * sexual abstinence, or~ * vasectomy of the partner~* Pregnant or lactating women~* History, risk factor or retinal pathology that increases the risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): evidence of retinal pathology that is considered a risk factor for RVO or CSR, or a history of retinal detachment, central serous chorioretinopathy or reti-nal vein thrombosis. The risk factors for RVO are listed below:~  * Uncontrolled glaucoma with intraocular pressures \> 21 mm Hg,~ * Serum cholesterol ≥ Grade 2 (≥ 7.75 mmol/L),~ * Hypertriglyceridemia ≥ Grade 2 (≥ 3.42 mmol/L), Hyperglycemia (fasting) ≥ Grade 2 (≥ 8.9 mmol/L).~* History of clinically significant cardiac dysfunction including:~  * Myocardial infarction,~ * Severe/unstable angina pectoris,~ * Symptomatic congestive heart failure (NYHA stage ≥ 2),~ * cerebrovascular accident or transient ischemic attack within the previous 6 months,~ * History of congenital long QT syndrome or mean QTcF \> 450 msec or uncorrectable electrolyte abnormalities,~ * Hypertension \> Grade 2 not controlled by medications~ * Left ventricular ejection fraction (LVEF) \< 50%, or~ * Uncontrolled arrhythmias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): all patients will be treated with Vemurafenib + Cobimetinib

Based on this trial design, predict the completion outcome and termination type (if applicable).